GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option ... - MarketWatch
GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option ... MarketWatch - About AFFiRiS AFFiRiS GmbH develops peptide-based vaccines for the treatment of Alzheimer's disease, atherosclerosis and other diseases that urgently ... Glaxo, Affiris ink $553 mln Alzheimer vaccine deal |
Original post: GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option ... - MarketWatch by ©2008 Google at alzheimers treatment - Google News
Blog tag: Alzheimers treatment
Technorati tag: Alzheimers treatment